Metronidazole Inhibitors
2 drugsAbout Metronidazole
Metronidazole is a nitroimidazole antibiotic targeting anaerobic bacteria and parasites. Its nitro group is reduced within susceptible cells, creating cytotoxic intermediates that damage DNA. This mechanism makes it a valuable drug target for treating a range of infections.
Metronidazole is a clinically validated target, evidenced by two FDA-approved drugs. However, there is currently no genetic evidence directly linking metronidazole's target to specific diseases.
Two FDA-approved drugs contain metronidazole: PYLERA and BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE. Both drugs are small molecules and are marketed by LABS JUVISE and PH HEALTH, respectively.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Small Intestine Bacterial Overgrowth with only 1 trials.
Top Drugs
The competitive landscape includes two companies with approved drugs: LABS JUVISE and PH HEALTH.
Low market concentration suggests relatively low barriers to entry for new competitors.
Drug Modality Landscape
Modalities
Routes of Administration
Metronidazole is amenable to small molecule drugs, with oral options available for convenient dosing.
The lack of diverse modalities represents a whitespace opportunity for novel therapeutic approaches like antibodies or biologics.
Clinical Trials 157 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 26 | 22 | 1 | 3 | 96% |
| Phase 2 | 38 | 21 | 5 | 12 | 81% |
| Phase 3 | 33 | 27 | 3 | 3 | 90% |
| Phase 4 | 60 | 43 | 7 | 10 | 86% |
Top Sponsors
By Modality
Top Conditions
Drug Approval Timeline (2006 - 2023)
Helicobacter pylori Infection
The first drug was approved in 2006 (PYLERA), with the most recent in 2023.
The 18-year span between approvals indicates a potentially slow-growing but persistent market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 96 clinical trials targeting Metronidazole.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities